Trial Profile
A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Zika virus vaccine-Sanofi (Primary) ; Aluminium hydroxide
- Indications Zika virus infection
- Focus Adverse reactions
- 01 Sep 2020 At study initiation, analysis of the endpoints at 6 months was planned to take place on day 180 (week 26), but this timepoint was amended on 27 Feb 2017, to day 196 (week 28) to harmonise timepoints with other concurrent trials on the ZPIV vaccine.
- 01 Sep 2020 According to results published in The Lancet Infectious Diseases, the Henry M Jackson Foundation for the Advancement of Military Medicine is the funder of the study.
- 01 Sep 2020 Results published in The Lancet Infectious Diseases